Week in Review: Fosun Ends $531 Million Deal with Sellas

Fosun Pharma ended its $531 million out-licensing deal with Sellas Clinicals Holding, after Sellas did not complete making its upfront payment; the US-based Orthopedics division of Shanghai’s MicroPort Scientific will partner with MB Innovations to design new products; Transgene SA updated the progress of its immunotherapeutic portfolio in its 50-50 joint venture with Tianjin Tasly Pharma; Uni-Bio Science reported that its treatment for osteoporosis, Uni-PTH, produced a statistically significant improvement in bone mass during a Phase III trial; and the CFDA granted Fast Track designation to Jiangsu NHWA’s in-licensed epilepsy treatment, DP-VPA. More details…. Stock Symbols: (SHA: 600196; HK: 02196) (HK: 0853) (PA: TNG) (SHA: 600535) (HK: 690) (SHE: 002262) Share this with colleagues: // //